Lethal Arrhythmia (Torsade de Pointes) in COVID-19: An Event Synergistically Induced by Viral Associated Cardiac Injury, Hyperinflammatory Response, and Treatment Drug?
Open Access
- 1 January 2020
- journal article
- case report
- Published by SAGE Publications in Clinical Medicine Insights: Case Reports
- Vol. 13
Abstract
Arrhythmias in patients with coronavirus disease 2019 (COVID-19) are prevalent and deserve special attention because they are associated with an increased risk of fatal outcome. The mechanism of arrhythmia in COVID-19 remains unclear. Here, we report our first case of confirmed COVID-19 with documented Torsade de Pointes (TdP). A 64-year-old woman, previously healthy, presented to our emergency department with progressive shortness of breath, dry cough, and 1 week of fever. She was treated with chloroquine phosphate, meropenem, and ciprofloxacin. After 5 days of admission, her condition deteriorated and she was admitted to the intensive care unit. The patient had two episodes of malignant arrhythmias within 24 hours. The former was TdP, and the latter was a fatal pulseless ventricular tachycardia that occured even after chloroquine was discontinued. There was evidence of cardiac injury shown by increased serum level of troponin I. We propose a synergistic concept of lethal arrhythmia due to direct severe acute respiratory syndrome coronavirus (SARS-CoV)-2-associated cardiac injury, hyperinflammatory response, and drug-induced arrhythmia.Keywords
This publication has 45 references indexed in Scilit:
- Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritisEuropean Heart Journal, 2016
- Drug-induced QT interval prolongation and torsades de pointesCanadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2016
- Locomotor-Respiratory Coupling in Wheelchair Racing Athletes: A Pilot StudyFrontiers in Physiology, 2016
- Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized PatientsCirculation: Cardiovascular Quality and Outcomes, 2013
- Interleukin-6 and cytochrome-P450, reason for concern?Rheumatology International, 2012
- Prevention of Torsade de Pointes in Hospital SettingsJACC, 2010
- Fluid, electrolyte and acid–base disorders associated with antibiotic therapyNature Reviews Nephrology, 2009
- Drug-Induced Prolongation of the QT IntervalNew England Journal of Medicine, 2004
- Torsade de pointes tachycardia as a rare manifestation of acute enteroviral myocarditisHeart, 2001
- Torsade de pointes due to coxsackie B3 myocarditisClinical Cardiology, 1987